EMA concludes review of weight management medicine Mysimba

View source ↗

Summary

The EMA concluded its review of Mysimba, confirming that benefits continue to outweigh risks and noting new risk minimisation measures and additional informatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Mysimba (naltrexone/bupropion)

Snippet

Benefits continue to outweigh risks, with new risk minimisation measures and more information to be provided about long-term effect on the heart